AcelRx Pharmaceuticals Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 54
Employees
  • Stock Symbol
  • ACRX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $0.48
  • (As of Tuesday Closing)

AcelRx Pharmaceuticals General Information

Description

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.

Contact Information

Website
www.acelrx.com
Formerly Known As
Surx
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Stock Exchange
NAS
Primary Office
  • 351 Galveston Drive
  • Redwood City, CA 94063
  • United States
+1 (650) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AcelRx Pharmaceuticals Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.48 $0.47 $0.43 - $2.94 $60.3M 128M 1.17M -$0.33

AcelRx Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 88,994 107,153 116,340 127,052
Revenue 3,554 5,416 2,289 2,151
EBITDA (35,140) (39,110) (52,537) (35,152)
Net Income (36,100) (40,379) (53,240) (47,149)
Total Assets 72,263 66,295 91,356 120,533
Total Debt 20,396 25,599 29,757 11,991
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AcelRx Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AcelRx Pharmaceuticals‘s full profile, request access.

Request a free trial

AcelRx Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore AcelRx Pharmaceuticals‘s full profile, request access.

Request a free trial

AcelRx Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of the
Pharmaceuticals
Redwood City, CA
54 As of 2020
00000
000000 - 000 00000

000000 0

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
00000000000 0000000
Ardsley, NY
000 As of 0000
00000
0.00 0000-00-00
000000&0

00000 00

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse c
000000000000000
Solana Beach, CA
0 As of 0000
0000
000000 - 000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AcelRx Pharmaceuticals Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Acorda Therapeutics Formerly VC-backed Ardsley, NY 000 00000 000000&0
00000 000000 Formerly VC-backed Solana Beach, CA 0 0000 000000 - 000 0000
00000 000000000000 Formerly VC-backed Bridgewater, NJ 0000 00000 000000&0
00000000 000000000 Corporation Henderson, NV 000 00000 000000 - 000 00000
0000 000000000000 Formerly VC-backed Bridgewater, NJ 000 00000 00000000000 00000
You’re viewing 5 of 11 competitors. Get the full list »

AcelRx Pharmaceuticals Patents

AcelRx Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2784486-T3 Apparatus and methods for dispensing oral transmucosal dosage forms Active 30-Oct-2015 0000000000
EP-3682915-A1 Apparatus and methods for dispensing oral transmucosal dosage forms Pending 30-Oct-2015 0000000000 0
EP-3368097-A1 Apparatus and methods for dispensing oral transmucosal dosage forms Granted 30-Oct-2015 0000000000
EP-3368097-B1 Apparatus and methods for dispensing oral transmucosal dosage forms Active 30-Oct-2015 0000000000
EP-3368097-A4 Apparatus and methods for dispensing oral transmucosal dosage forms Granted 30-Oct-2015 A61J7/0076 0
To view AcelRx Pharmaceuticals’s complete patent history, request access »

AcelRx Pharmaceuticals Executive Team (18)

Name Title Board Seat Contact Info
Vincent Angotti Chief Executive Officer & Board Member
Raffi Asadorian Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Larry Hamel Chief Development Officer
Badri Dasu Executive
Pamela Palmer Ph.D Chief Medical Officer & Founder
You’re viewing 5 of 18 executive team members. Get the full list »

AcelRx Pharmaceuticals Board Members (12)

Name Representing Role Since
Adrian Adams Self Chairman & Board Member 000 0000
Howard Rosen AcelRx Pharmaceuticals Board Member 000 0000
Jill Broadfoot Self Board Member 000 0000
Mark Edwards Self Board Member 000 0000
Mark Wan Three Arch Partners Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

AcelRx Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AcelRx Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 10-Jan-2022 0000000000 000.00 Pharmaceuticals
To view AcelRx Pharmaceuticals’s complete acquisitions history, request access »